CTRI/2024/04/066128
Not yet recruiting
Phase 4
A prospective, single-arm, single-centre study to evaluate the CT angiographic outcomes after implantation of MeRes100™ Sirolimus Eluting BioResorbable Vascular Scaffold System in coronary artery disease patients. - MeRes100 CIMS-CT Study
Dr Keyur Parikh0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery
- Sponsor
- Dr Keyur Parikh
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patient who has been implanted with MeRes100 BRS from February 2021 to March 2023\.
- •2\. Patient has given written informed consent for participation prior to enrolment.
- •3\. Patient is willing to undergo all study procedures and follow\-up requirements.
Exclusion Criteria
- •1\. Any condition, which in the Investigator’s opinion would preclude safe participation of patient in the study.
- •2\. Patient participating in another clinical investigation.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
A study to assess Efficacy and safety of Ayurvedic Kadha in health and immunity related parameters in mild COVID-19 patients.Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2021/03/032072MARC Laboratories Ltd50
Recruiting
Not Applicable
PASSAGE Clinical TrialJPRN-jRCT2032220496Kawahara Kazuo51
Active, not recruiting
Phase 3
Efficacy and safety of Sirolimus granules twice daily administration in patients with intractuable vascular malformationsIntractable vascular malformationsVascular disordersD054079JPRN-jRCTs031200055Mochizuki Shinji11
Completed
Not Applicable
OFT-G1-301 StudyCongenital heart diseaseJPRN-jRCT1080224691TEIJIN LIMITED / TEIJIN PHARMA LIMITED30
Not yet recruiting
Phase 4
A study of Romiplostim Powder for Injection in patientsCTRI/2021/08/035609Intas Pharmaceuticals Limited